Eli Lilly presented new phase 3 clinical trial data showing arzoxifene, an investigational selective estrogen receptor modulator (SERM), was superior to Evista (raloxifene) at increasing bone mineral density (BMD) in the lumbar spine, total hip and femoral neck, and at suppressing bone turnover as assessed by serum markers of bone metabolism.
The NEXT study was a double-blind, active comparator, controlled, 12-month study. The study’s primary endpoint was lumbar spine BMD. Secondary objectives included assessment of femoral neck and total hip BMD, serum bone turnover markers, mammographic breast density and safety.
For more information please call (800) 545-5979 or visit www.lilly.com.